Kaskela Law is investigating potential breach of fiduciary duty claims concerning Agilon Health, Inc. (NYSE: AGL) on behalf of the company’s long-term investors.
Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company’s stock between April 15, 2021 and February 27, 2024. According to the complaint, during that time period Agilon and several of the company’s senior executive officers made a series of materially false and misleading statements to investors about Agilon’s medical costs.
As further detailed in the complaint, as the true information about the company’s higher medical costs was disclosed to the market, shares of the company’s stock significantly declined in value, harming the company’s long-term investors. Specifically, Agilon’s stock declined from a trading price of over $44.00 per share to less than $6.50 per share (prior to the company’s March 2026 1-for-25 reverse stock split), a decline of approximately 85% in value.
The investigation seeks to determine whether the members of Agilon’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
Current Agilon Health shareholders who purchased or acquired AGL shares prior to May 1, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at 484-229-0750, or by completing the form on this page.